|
|
World’s Leading Proxy Advisory Firms ISS and Glass Lewis Recommend T2 Biosystems Stockholders Vote “FOR” the Charter Amendment Proposal – To Increase the Number of Authorized Shares of Common Stock
|
|
|
T2 Biosystems Reminds Stockholders to Vote at the Upcoming Annual Meeting
|
|
|
T2 Biosystems Announces First Quarter 2021 Financial Results
|
|
|
T2 Biosystems Accelerates Product Development Initiatives Under Existing BARDA Contract
|
|
|
T2 Biosystems Announces Meta-analysis of Controlled Studies in Peer-Reviewed Medical Journal Highlighting the Benefits of T2MR Technology Compared to Blood Culture
|
|
|
T2 Biosystems to Report First Quarter 2021 Financial Results on May 6, 2021
|
|
|
T2 Biosystems CEO Shares Personal Heart Transplant and Sepsis Survival Story in Newly Released Book
|
|
|
T2 Biosystems Reports Granting of Inducement Award
|
|
|
T2 Biosystems Announces Fourth Quarter & Full Year 2020 Financial Results
|
|
|
T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
|
